FindTrial
Sign In

Vorolanib

DRUG5 trials

Sponsors

Washington University School of Medicine, Vanderbilt-Ingram Cancer Center, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Betta Pharmaceuticals Co., Ltd.

Conditions

Extensive-stage Small Cell Lung CancerGastric CancerGastroesophageal Junction AdenocarcinomaHepatic Impairment (HI)Hepatocellular CarcinomaKidney CancerNon-small Cell Lung CancerRCC

Phase 1

Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
TerminatedNCT03511222
Washington University School of MedicineGastric Cancer, Gastroesophageal Junction Adenocarcinoma, Hepatocellular Carcinoma +1
Start: 2018-09-11End: 2020-05-28Updated: 2020-07-29
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
CompletedNCT03583086
Vanderbilt-Ingram Cancer CenterNon-small Cell Lung Cancer, Refractory Thoracic Tumors, Small-Cell Lung Cancer +1
Start: 2018-07-10End: 2024-04-27Updated: 2024-10-08
Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients
Not yet recruitingNCT06577961
Cancer Institute and Hospital, Chinese Academy of Medical SciencesKidney Cancer, RCC, Renal Cell Carcinoma
Start: 2024-08-31End: 2027-08-31Target: 37Updated: 2024-08-29
Pharmacokinetic Study of Vorolanib Tablets in Trial Participants With Hepatic Impairment
RecruitingNCT07809802
Betta Pharmaceuticals Co., Ltd.Hepatic Impairment (HI)
Start: 2026-09-01End: 2027-06-01Target: 36Updated: 2026-09-09
Pharmacokinetic Study of Vorolanib Tablets in Trial Participants With Hepatic Impairment
RecruitingNCT07809802
Betta Pharmaceuticals Co., Ltd.Hepatic Impairment (HI)
Start: 2026-09-01End: 2027-06-01Target: 36Updated: 2026-09-09

Phase 2

Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
TerminatedNCT04373369
Washington University School of MedicineExtensive-stage Small Cell Lung Cancer
Start: 2020-10-07End: 2025-08-11Updated: 2025-11-03

Related Papers

Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology2022-03-059 citations
Phase I/II study of nivolumab plus vorolanib in patients with thoracic malignancies: Interim efficacy of the SCLC and primary refractory NSCLC cohorts, and safety data across all cohorts.
Journal of Clinical Oncology2021-05-205 citations
Phase I/II study of vorolanib plus nivolumab in patients with thoracic malignancies: immunotherapy (IO) correlatives to differentiate responders from nonresponders.
Journal of Clinical Oncology2020-05-202 citations
Abstract CT171: Phase I/II study to evaluate the safety and preliminary activity of nivolumab in combination with vorolanib in patients with refractory thoracic tumors
Cancer Research2019-07-01
Abstract CT171: Phase I/II study to evaluate the safety and preliminary activity of nivolumab in combination with vorolanib in patients with refractory thoracic tumors
Clinical Trials2019-07-01
A phase Ib trial of anti-VEGFR/PDGFR vorolanib combined with immune checkpoint inhibitors (CPIs) in solid tumors.
Journal of Clinical Oncology2019-01-29